Literature DB >> 14755675

Prostate carcinoma: opportunities for translational research.

T J FitzGerald1, Edmund Simon, Joshua Meyer.   

Abstract

Adenocarcinoma of the prostate continues to be a major health concern. Although modern screening techniques have increased the number of men presenting with early stage disease, a significant population of men will present with intermediate or advanced pathological risk factors for recurrence. There are defined limitations in outcome with traditional therapies including surgery, radiation therapy, and hormone manipulation. Patients with intermediate and high-risk factors for treatment failure are candidates for protocols using translational research strategies incorporated into studies currently in development. These strategies may be able to selectively treat expression products of tumor and thus be more selective in the target for treatment. Carefully designed studies using these translational strategies have great potential in improving clinical outcome, tumor kill, and normal tissue tolerance in the care of these patients. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755675     DOI: 10.1002/jcb.10693

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

Review 1.  Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.

Authors:  T J Fitzgerald; Tao Wang; Hira Lal Goel; Jiayi Huang; Gary Stein; Jane Lian; Roger J Davis; Steven Doxsey; K C Balaji; Jesse Aronowitz; Lucia R Languino
Journal:  Expert Rev Anticancer Ther       Date:  2008-06       Impact factor: 4.512

2.  Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.

Authors:  Tao Wang; Michael R Alavian; Hira Lal Goel; Lucia R Languino; Thomas J Fitzgerald
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

3.  Molecular targets for radiation oncology in prostate cancer.

Authors:  Tao Wang; Lucia R Languino; Jane Lian; Gary Stein; Michael Blute; Thomas J Fitzgerald
Journal:  Front Oncol       Date:  2011-07-13       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.